Infarcted Myocardium-Primed Dendritic Cells Improve Remodeling and Cardiac Function after Myocardial Infarction by Modulating the Regulatory T Cell and Macrophage Polarization

Circulation

Volumn 135, Issue 15, 2017, Pages 1444-1457

  Choo, Eun Ho ^a   Lee, Jun Ho ^b,c   Park, Eun Hye ^a   Park, Hyo Eun ^a   Jung, Nam Chul ^c   Kim, Tae Hoon ^a   Koh, Yoon Seok ^a   Kim, Eunmin ^a   Seung, Ki Bae ^a   Park, Cheongsoo ^d   Hong, Kwan Soo ^d   Kang, Kwonyoon ^a   Song, Jie Young ^e   Seo, Han Geuk ^f   Lim, Dae Seog ^b   Chang, Kiyuk ^a  

^a The Catholic University of Korea   (South Korea)

^b CHA University   (South Korea)

^c Pharos Vaccine Inc   (South Korea)

^d Korea Basic Science Institute (KBSI)   (South Korea)

^e Korea Institute of Radiation and Medical Science   (South Korea)

^f Konkuk University   (South Korea)

Author keywords

dendritic cells; heart failure; macrophage; myocardial infarction; regulatory T cells; ventricular remodeling

Indexed keywords

TUMOR NECROSIS FACTOR; ANTIGEN; BIOLOGICAL MARKER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW DERIVED DENDRITIC CELL; CARDIOVASCULAR MAGNETIC RESONANCE; CELL LYSATE; CELL POLARITY; CONTROLLED STUDY; HEART FUNCTION; HEART INFARCTION; HEART VENTRICLE REMODELING; INGUINAL LYMPH NODE; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MACROPHAGE; MEDIASTINUM LYMPH NODE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SPLEEN; ADOPTIVE TRANSFER; ANIMAL; BIOLOGICAL THERAPY; CARDIAC MUSCLE; CELL MOTION; DENDRITIC CELL; DISEASE MODEL; DRUG EFFECTS; HEART LEFT VENTRICLE FUNCTION; IMMUNIZATION; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MALE; METABOLISM; MYOCARDIAL INFARCTION; NEOVASCULARIZATION (PATHOLOGY); NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PATHOPHYSIOLOGY;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS; BIOMARKERS; CELL MOVEMENT; CELL- AND TISSUE-BASED THERAPY; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; IMMUNIZATION; LYMPHOCYTE ACTIVATION; MACROPHAGES; MAGNETIC RESONANCE IMAGING; MALE; MICE; MYOCARDIAL INFARCTION; MYOCARDIUM; NEOVASCULARIZATION, PATHOLOGIC; T-LYMPHOCYTES, REGULATORY; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 85013374549     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.116.023106     Document Type: Article

References (39)

1. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Soliman EZ, Sorlie PD, Sotoodehnia N, Turan TN, Virani SS, Wong ND, Woo D, Turner MB; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation. 2012;125:188-197. doi: 10.1161/CIR.0b013e3182456d46.
2. Nahrendorf M, Pittet MJ, Swirski FK. Monocytes: protagonists of infarct inflammation and repair after myocardial infarction. Circulation. 2010;121:2437-2445. doi: 10.1161/CIRCULATIONAHA. 109.916346.
3. Seropian IM, Toldo S, Van Tassell BW, Abbate A. Anti-inflammatory strategies for ventricular remodeling following ST-segment elevation acute myocardial infarction. J Am Coll Cardiol. 2014;63:1593-1603. doi: 10.1016/j.jacc.2014.01.014.
4. Lee WW, Marinelli B, van der Laan AM, Sena BF, Gorbatov R, Leuschner F, Dutta P, Iwamoto Y, Ueno T, Begieneman MP, Niessen HW, Piek JJ, Vinegoni C, Pittet MJ, Swirski FK, Tawakol A, Di Carli M, Weissleder R, Nahrendorf M. PET/MRI of inflammation in myocardial infarction. J Am Coll Cardiol. 2012;59:153-163. doi: 10.1016/j.jacc.2011.08.066.
5. Weirather J, Hofmann UD, Beyersdorf N, Ramos GC, Vogel B, Frey A, Ertl G, Kerkau T, Frantz S. Foxp3+ CD4+ T cells improve healing after myocardial infarction by modulating monocyte/macrophage differentiation. Circ Res. 2014;115:55-67. doi: 10.1161/ CIRCRESAHA.115.303895.
6. Bluestone JA, Buckner JH, Fitch M, Gitelman SE, Gupta S, Hellerstein MK, Herold KC, Lares A, Lee MR, Li K, Liu W, Long SA, Masiello LM, Nguyen V, Putnam AL, Rieck M, Sayre PH, Tang Q. Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Sci Transl Med. 2015;7:315ra189. doi: 10.1126/scitranslmed. aad4134.
7. Miyara M, Ito Y, Sakaguchi S. TREG-cell therapies for autoimmune rheumatic diseases. Nat Rev Rheumatol. 2014;10:543-551. doi: 10.1038/nrrheum.2014.105.
8. Trzonkowski P, Bieniaszewska M, Juścińska J, Dobyszuk A, Krzystyniak A, Marek N, Myśliwska J, Hellmann A. First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127-T regulatory cells. Clin Immunol. 2009;133:22-26. doi: 10.1016/j. clim.2009.06.001.
9. Anzai A, Anzai T, Nagai S, Maekawa Y, Naito K, Kaneko H, Sugano Y, Takahashi T, Abe H, Mochizuki S, Sano M, Yoshikawa T, Okada Y, Koyasu S, Ogawa S, Fukuda K. Regulatory role of dendritic cells in postinfarction healing and left ventricular remodeling. Circulation. 2012;125:1234-1245. doi: 10.1161/CIRCULATIONAHA. 111.052126.
10. Jung NC, Kim HJ, Kang MS, Lee JH, Song JY, Seo HG, Bae YS, Lim DS. Photodynamic therapy-mediated DC immunotherapy is highly effective for the inhibition of established solid tumors. Cancer Lett. 2012;324:58-65. doi: 10.1016/j. canlet.2012.04.024.
11. Lee JH, Kim TH, Park HE, Lee EG, Jung NC, Song JY, Seo HG, Seung KB, Chang K, Lim DS. Myosin-primed tolerogenic dendritic cells ameliorate experimental autoimmune myocarditis. Cardiovasc Res. 2014;101:203-210. doi: 10.1093/cvr/cvt246.
12. Lutz MB, Suri RM, Niimi M, Ogilvie AL, Kukutsch NA, Rössner S, Schuler G, Austyn JM. Immature dendritic cells generated with low doses of GM-CSF in the absence of IL-4 are maturation resistant and prolong allograft survival in vivo. Eur J Immunol. 2000;30:1813-1822. doi: 10.1002/1521-4141(200007)30 CO;2-8.
13. Stoop JN, Harry RA, von Delwig A, Isaacs JD, Robinson JH, Hilkens CM. Therapeutic effect of tolerogenic dendritic cells in established collagen-induced arthritis is associated with a reduction in Th17 responses. Arthritis Rheum. 2010;62:3656-3665. doi: 10.1002/art.27756.
14. Hermans IF, Ritchie DS, Yang J, Roberts JM, Ronchese F. CD8+ T cell-dependent elimination of dendritic cells in vivo limits the induction of antitumor immunity. J Immunol. 2000;164:3095-3101.
15. Moon H, Park HE, Kang J, Lee H, Cheong C, Lim YT, Ihm SH, Seung KB, Jaffer FA, Narula J, Chang K, Hong KS. Noninvasive assessment of myocardial inflammation by cardiovascular magnetic resonance in a rat model of experimental autoimmune myocarditis. Circulation. 2012;125:2603-2612. doi: 10.1161/CIRCULATIONAHA. 111.075283.
16. Lim DS, Kang MS, Jeong JA, Bae YS. Semi-mature DC are immunogenic and not tolerogenic when inoculated at a high dose in collagen-induced arthritis mice. Eur J Immunol. 2009;39:1334-1343. doi: 10.1002/eji.200838987.
17. Burchfield JS, Xie M, Hill JA. Pathological ventricular remodeling: mechanisms: part 1 of 2. Circulation. 2013;128:388-400. doi: 10.1161/CIRCULATIONAHA.113.001878.
18. Gajarsa JJ, Kloner RA. Left ventricular remodeling in the postinfarction heart: a review of cellular, molecular mechanisms, and therapeutic modalities. Heart Fail Rev. 2011;16:13-21. doi: 10.1007/s10741-010-9181-7.
19. Lutgens E, Daemen MJ, de Muinck ED, Debets J, Leenders P, Smits JF. Chronic myocardial infarction in the mouse: cardiac structural and functional changes. Cardiovasc Res. 1999;41:586-593.
20. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction: experimental observations and clinical implications. Circulation. 1990;81:1161-1172.
21. Fröhlich GM, Meier P, White SK, Yellon DM, Hausenloy DJ. Myocardial reperfusion injury: looking beyond primary PCI. Eur Heart J. 2013;34:1714-1722. doi: 10.1093/eurheartj/eht090.
22. Jelani A, Jugdutt BI. STEMI and heart failure in the elderly: role of adverse remodeling. Heart Fail Rev. 2010;15:513-521. doi: 10.1007/s10741-010-9177-3.
23. Beyersdorf N, Balbach K, Hünig T, Kerkau T. Large-scale expansion of rat CD4+ CD25+ T(reg) cells in the absence of T-cell receptor stimulation. Immunology. 2006;119:441-450. doi: 10.1111/j.1365-2567.2006.02455.x.
24. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol. 2003;21:685-711. doi: 10.1146/ annurev.immunol.21.120601.141040.
25. Hackstein H, Thomson AW. Dendritic cells: emerging pharmacological targets of immunosuppressive drugs. Nat Rev Immunol. 2004;4:24-34. doi: 10.1038/nri1256.
26. Morelli AE, Thomson AW. Dendritic cells: regulators of alloimmunity and opportunities for tolerance induction. Immunol Rev. 2003;196:125-146.
27. Morelli AE, Thomson AW. Tolerogenic dendritic cells and the quest for transplant tolerance. Nat Rev Immunol. 2007;7:610-621. doi: 10.1038/nri2132.
28. Menges M, Rössner S, Voigtländer C, Schindler H, Kukutsch NA, Bogdan C, Erb K, Schuler G, Lutz MB. Repetitive injections of dendritic cells matured with tumor necrosis factor alpha induce antigen-specific protection of mice from autoimmunity. J Exp Med. 2002;195:15-21.
29. Stoop JN, Robinson JH, Hilkens CM. Developing tolerogenic dendritic cell therapy for rheumatoid arthritis: what can we learn from mouse models? Ann Rheum Dis. 2011;70:1526-1533. doi: 10.1136/ard.2011.151654.
30. Giannoukakis N, Phillips B, Finegold D, Harnaha J, Trucco M. Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients. Diabetes Care. 2011;34:2026-2032. doi: 10.2337/dc11-0472.
31. Maldonado RA, von Andrian UH. How tolerogenic dendritic cells induce regulatory T cells. Adv Immunol. 2010;108:111-165. doi: 10.1016/B978-0-12-380995-7.00004-5.
32. Frangogiannis NG. The inflammatory response in myocardial injury, repair, and remodelling. Nat Rev Cardiol. 2014;11:255-265. doi: 10.1038/nrcardio.2014.28.
33. Swirski FK, Nahrendorf M. Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure. Science. 2013;339:161-166. doi: 10.1126/science.1230719.
34. Leuschner F, Rauch PJ, Ueno T, Gorbatov R, Marinelli B, Lee WW, Dutta P, Wei Y, Robbins C, Iwamoto Y, Sena B, Chudnovskiy A, Panizzi P, Keliher E, Higgins JM, Libby P, Moskowitz MA, Pittet MJ, Swirski FK, Weissleder R, Nahrendorf M. Rapid monocyte kinetics in acute myocardial infarction are sustained by extramedullary monocytopoiesis. J Exp Med. 2012;209:123-137. doi: 10.1084/jem.20111009.
35. Nahrendorf M, Swirski FK, Aikawa E, Stangenberg L, Wurdinger T, Figueiredo JL, Libby P, Weissleder R, Pittet MJ. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med. 2007;204:3037-3047. doi: 10.1084/jem.20070885.
36. Nahrendorf M, Swirski FK. Regulating repair: regulatory T cells in myocardial infarction. Circ Res. 2014;115:7-9. doi: 10.1161/ CIRCRESAHA.114.304295.
37. Frenkel D, Pachori AS, Zhang L, Dembinsky-Vaknin A, Farfara D, Petrovic-Stojkovic S, Dzau VJ, Weiner HL. Nasal vaccination with troponin reduces troponin specific T-cell responses and improves heart function in myocardial ischemia-reperfusion injury. Int Immunol. 2009;21:817-829. doi: 10.1093/intimm/ dxp051.
38. Dardik R, Loscalzo J, Inbal A. Factor XIII (FXIII) and angiogenesis. J Thromb Haemost. 2006;4:19-25. doi: 10.1111/j.1538-7836.2005.01473.x.
39. Smadja DM, Cornet A, Emmerich J, Aiach M, Gaussem P. Endothelial progenitor cells: characterization, in vitro expansion, and prospects for autologous cell therapy. Cell Biol Toxicol. 2007;23:223-239. doi: 10.1007/s10565-007-0177-6.